 Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration FDA accepted the New Drug Application NDA for accelerated review of ZokinvyTM lonafarnib for treatment of Progeria and Progeroid Laminopathies. The FDA granted Priority Review with a Prescription Drug User Fee Act PDUFA target action date of November 20, 2020. The FDA is not currently planning to hold an advisory committee meeting to discuss this application. Zokinvy for treatment of Progeria and Progeroid Laminopathies has been granted Rare Pediatric Disease Designation. 